Atmos Energy Corp

Discover why Atmos Energy Corp may be undervalued: solid 10% earnings growth, low debt, and a strategic path to renewable gas and smart‑meter revenue.

Atmos Energy Corp demonstrates operational stability and commitment to grid reliability through strategic investments in renewable energy integration, infrastructure modernization, and advanced technologies, positioning itself for success in a rapid…

Atmos Energy Corporation’s stock price has seen a recent uptick, driven by market confidence in the company’s operational trajectory and financial health, with Mizuho Securities revising its price target to reflect a higher upside.

Atmos Energy Corp. has seen a 46.1% return on investment over the past three years, driven by a shift in the US natural-gas market and a strong financial position, but faces potential risks from regulatory changes, infrastructure costs, and evolving…

Atmos Energy Corp. faces significant technical and economic challenges as it navigates the transition to a low-carbon grid, but its robust gas generation portfolio and proactive investment in grid stability and renewable integration strategies posit…

Atmos Energy Corp. has demonstrated resilience in the utilities sector, driven by its expertise in natural gas marketing and procurement services, as well as its effective management of storage and pipeline assets.

Atmos Energy Corp has delivered a strong third quarter earnings report, exceeding expectations with a 15% year-over-year increase in net income and a 20% increase in customer growth.

Atmos Energy Corp’s stock has shown stable growth, with a recent close price above its 52-week high, making it an attractive investment opportunity for those seeking a reliable energy company.

Atmos Energy Corp’s stock price remains stable, with increased buyer interest expected, but lacks direct news or updates.

Epsilon Healthcare Ltd has partnered with a leading healthcare provider to expand services, improve patient care, and enhance collaboration, while Wrkr Ltd reported strong Q2 earnings, Artrya Limited received FDA clearance for a new medical device, …